Encephalopathy cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
Line 3: Line 3:


==Overview==
==Overview==
Treatment of encephalopathy in very early stages is cost effective. Early intervention relieves forthcoming complications and the costs to support them.
Encephalopathy in its very early stages is cost effective. Early intervention relieves forthcoming complications and the costs that would have come along with them.


==Financial Costs==
==Financial Costs==

Revision as of 20:26, 27 July 2012

Encephalopathy

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Encephalopathy from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Electroencephalogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Encephalopathy cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Encephalopathy cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Encephalopathy cost-effectiveness of therapy

CDC on Encephalopathy cost-effectiveness of therapy

Encephalopathy cost-effectiveness of therapy in the news

Blogs on Encephalopathy cost-effectiveness of therapy

Directions to Hospitals Treating Encephalopathy

Risk calculators and risk factors for Encephalopathy cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]

Overview

Encephalopathy in its very early stages is cost effective. Early intervention relieves forthcoming complications and the costs that would have come along with them.

Financial Costs

  • Cost effectiveness of various therapies depends on the condition.
  • Hypothermia for neonatal encephalopathy - The incremental cost per disability-free life year gained was US$28,124 (£19,931 ; €26,920) as per the data of 2006 Organisation for Economic Co-operation and Development (OECD). [1]
  • Detection of minimal hepatic encephalopathy, especially using the inhibitory control test, and subsequent treatment with lactulose could substantially reduce societal costs by preventing motor vehicle accident. Net program savings over 5 years ranged from $1.7 to 3.6 million.[2]

References

  1. Regier DA, Petrou S, Henderson J; et al. (2010). "Cost-effectiveness of therapeutic hypothermia to treat neonatal encephalopathy". Value Health. 13 (6): 695–702. doi:10.1111/j.1524-4733.2010.00731.x. PMID 20561343.
  2. Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM (2012). "Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis". Hepatology. 55 (4): 1164–71. doi:10.1002/hep.25507. PMID 22135042. Unknown parameter |month= ignored (help)

Template:WH Template:WS